Sign in
Taking people in United StatesPhase 3

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

Key facts

Who runs it
Sanofi
Where
Atlanta, Boston, Charlotte, Cleveland, Columbus, Detroit, Fayetteville, Fontana, Margate, Middleburg Heights, New York, Palm Beach Gardens, Plano, Red Oak, Rochester, Sacramento, San Jose, Seattle, Tampa, Tustin, and Wichita Falls, United StatesSee the 21 sitesAlso in 18 other countries, 74 sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
124 people, planned
Started
26 Sept 2025
Expected to end
25 Dec 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Rilzabrutinib
  • Placebo
  • Glucocorticoid
Record updated
20 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Participants must have a clinical diagnosis of IgG4-RD confirmed by the Adjudication Committee
  • Participants meeting Step 1 Entry criteria of 2019 ACR/EULAR classification criteria for IgG4-RD and Total inclusion points are ≥20
  • Participants with active disease in at least 1 organ system, excluding lymph nodes, with active disease defined by an IgG4-RD Responder Index organ/site activity score ≥2 based on the manifestations of disease activity in the last 28 days
  • Participants with history or current involvement of at least 1 organ/site (excluding lymph nodes) affected with IgG4-RD
  • Participants with active IgG4-RD controlled for at least 2 weeks while on a stable dose of GC
  • Participants willing to taper off GC after starting IMP
  • Participants willing and able to participate in repeated study protocol mandated or clinically indicated imaging procedures to assess IgG4-RD such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), or ultrasound
  • Participants who have an up-to-date vaccination status as per local guidelines. The last dose of live vaccines should be received at least 30 days before Day 1
  • Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

Who cannot take part

  • Refractory nausea and vomiting, malabsorption, external biliary shunt, bariatric surgery, or significant bowel resection that would preclude adequate rilzabrutinib/placebo absorption
  • Planned major surgical procedure during the participation in this study
  • History of drug abuse within the previous 12 months
  • Prior participation in any rilzabrutinib studies or other BTK inhibitor studies
  • History of treatment with an investigational drug within 6 months or 5 half-lives of the investigational drug, whichever is longer
  • History of retroperitoneal fibrosis, sclerosing mesenteritis, fibrosing mediastinitis, or other overwhelmingly fibrotic expression of IgG4-RD that is the sole disease manifestation
  • Active malignancy or history of malignancy within 5 years before Day 1, except completely treated in situ carcinoma of the cervix, completely treated, and resolved nonmetastatic squamous or basal cell carcinoma of the skin
  • Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator
  • History of serious infections with the potential for recurrence (as judged by the Investigator), with less than 4 weeks interval between resolution of serious infection and first dose of study drug, or currently active moderate to severe infection at Screening (Grade 2 or higher)
  • Current or chronic history of liver disease unrelated to IgG4-RD
  • History of solid organ transplant
  • Laboratory abnormalities at the screening visit identified by the central laboratory The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
  • Meet any Step 2 Exclusion criteria from the 2019 ACR/EULAR classification criteria for IgG4-RD
  • Alcoholism or excessive alcohol use, defined as regular consumption of more than approximately 3 standard drinks per day

Where in United States

Also in 18 other countries, 74 sites

  • Emory University School of Medicine - Atlanta- Site Number : 8400013Atlanta, United StatesTaking people
  • Massachusetts General Hospital- Site Number : 8400008Boston, United StatesTaking people
  • Arthritis and Osteoporosis Consultants of the Carolinas- Site Number : 8400035Charlotte, United StatesTaking people
  • Cleveland Clinic - Cleveland- Site Number : 8400001Cleveland, United StatesContact: Danielle HaasTaking people
  • Ohio State University Wexner Medical Center- Site Number : 8400024Columbus, United StatesTaking people
  • Henry Ford Hospital- Site Number : 8400009Detroit, United StatesTaking people
  • Fayetteville, GeorgiaHospital not named in the registryContact: Celine LaluTaking people
  • Kaiser Permanente - Fontana Medical Center- Site Number : 8400015Fontana, United StatesTaking people
  • Life Clinical Trials - Margate - Colonial Drive- Site Number : 8400002Margate, United StatesContact: Ana AuzaTaking people
  • Paramount Medical Research and Consulting LLC- Site Number : 8400018Middleburg Heights, United StatesContact: Jackie WittenmyerTaking people
  • Icahn School of Medicine at Mount Sinai- Site Number : 8400014New York, United StatesTaking people
  • Vitalia Medical Research - Margate- Site Number : 8400025Palm Beach Gardens, United StatesContact: Delano BrooksTaking people
  • Plano, TexasHospital not named in the registryContact: Jayshree ChouhanTaking people
  • Epic Medical Research - Red Oak- Site Number : 8400003Red Oak, United StatesContact: Siby SpurgeonTaking people
  • Mayo Clinic in Rochester - Minnesota- Site Number : 8400017Rochester, United StatesContact: Christian CoyTaking people
  • University of California Davis Health- Site Number : 8400012Sacramento, United StatesTaking people
  • San Jose, CaliforniaHospital not named in the registryContact: Sara ViznyukTaking people
  • Velocity Clinical Research - Seattle- Site Number : 8400005Seattle, United StatesContact: Christeen DeNeuiTaking people
  • Tampa General Hospital - Tampa - General Circle- Site Number : 8400027Tampa, United StatesTaking people
  • Solace Clinical Research - Tustin- Site Number : 8400020Tustin, United StatesContact: Hikyhe OgannesianTaking people
  • Digestive Health Research of North Texas- Site Number : 8400021Wichita Falls, United StatesContact: Sarah SparkmanTaking people

About the trial

What the trial wants to find out

This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients with active IgG4-RD.

Read full original descriptionShow less

The purpose of this study is to measure time to adjudicated IgG4-RD clinical disease flare, and other relevant efficacy endpoints including flare-free rate, control of IgG4-RD disease activity, use of GC rescue and safety parameters such as treatment-emergent adverse events, clinical laboratory values and electrocardiograms (ECG) in participants aged 18 years and above, diagnosed with IgG4-RD and treated with rilzabrutinib tablets over a 52-week placebo-controlled period.

Study details include:

The study duration will be up to 60 weeks, including a Screening period of 4 to 6 weeks, a 52-week double blind treatment period, and 2 weeks of follow up (plus an optional OLE of 108 weeks).

The number of visits will be 16 (plus an optional 9 visits during the OLE).

The 2 groups in the trial

  • RilzabrutinibTreatment being tested

    Treatment: Rilzabrutinib and Glucocorticoid

  • PlaceboPlacebo, for comparison

    Treatment: Placebo and Glucocorticoid

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult Participants With Active IgG4-related Disease
Record updated
20 October 2026